Preventing Anal Cancer: Results from the ANCHOR Study

Joel M. Palefsky, MD, FRCP (C)
Professor of Medicine, Division of Infectious Diseases
University of California, San Francisco, CA



CME VIDEOTop of page

How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Survey

About the Presenter:Top of page

Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine and Infectious Diseases at the University of California San Francisco School of Medicine. He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center. He is the vice-chair of the National Cancer Institute (NCI)-supported AIDS Malignancy Consortium. He is the chair of the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study, a national multi-site NIH study designed to determine whether treatment of anal cancer precursor lesions prevents the development of anal cancer and to identify biomarkers of progression. He is founder and past president of the International Anal Neoplasia Society and is past president of the International Papillomavirus Society.

Learning Objectives: Top of page

At the completion of this educational session, participants will:
1. Understand the rationale for and design of the ANCHOR Study
2. Know the results of the ANCHOR Study
3. Be able to discuss the implications of the ANCHOR Study

CME Information:Top of page


This CME activity has approved for AMA PRA Category 1 Credit™ for March 23, 2022, as a live activity.  This activity will also be available as an enduring activity from March 24, 2022, through March 22, 2025.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

Accreditation Statement:Top of page


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement:Top of page

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement:Top of page

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.

- Dr. James F. Braun, DO (Course Director) has no relevant financial relationships to disclose.

- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.

- Dr. Joel M. Palefsky (Presenter) has had the following personal financial relationships in the past 24 months with manufacturers of the products or services that may be presented in this CME activity: Scientific Advisory Board Member, Grant Recipient, and Speaker at Merck; Consultant to Vir Biotechnologies, Antiva Biosciences, and Viron Therapeutics (w/Viron stock options.) Dr. Palefsky will support his presentation and clinical recommendations with the best available evidence from the medical literature, and will submit his slides in advance for adequate peer review.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Evaluation

You must be logged in to post a comment. Login | Register